Objectives: To examine trends in the prevalence of diagnosed atrial fibrillation (AF), its treatment with oral anticoagulants between 1994 and 2003, and predictors of anticoagulant treatment in 2003.
Methods: Analysis of electronic data from 131 general practices (about one million registered patients annually) contributing to the DIN-LINK database.
Results: From 1994 to 2003 the prevalence of “active” AF rose from 0.78% to 1.31% in men and from 0.79% to 1.15% in women. The proportion of patients with AF taking anticoagulants rose from 25% to 53% in men and from 21% to 40% in women. Most others received antiplatelets. The likelihood of receiving anticoagulants was greater for men and with increasing stroke risk. It decreased sharply with age after 75 years. Socioeconomic status, urbanisation and region had no influence. Non-steroidal anti-inflammatory drugs, antiplatelet drugs and ulcer healing drugs were associated with reduced likelihood of receiving anticoagulants, as were peptic ulcers, chronic gut disorders, anaemias, psychoses and poor compliance. Anticoagulant treatment was associated with several cardiovascular co-morbidities and drugs, possibly due to secondary care treatment. Nevertheless, only 56.5% of patients at very high risk of stroke were taking anticoagulants in 2003, whereas 38.2% of patients at low risk of stroke received anticoagulants.
Conclusions: This study confirms previously observed trends of increasing AF prevalence and warfarin treatment. Many patients who may benefit from anticoagulation still do not receive it, whereas others at lower risk of stroke do. The lower likelihood of women receiving anticoagulants is of particular concern.
- ACORN, A Classification of Residential Neighbourhoods
- AF, atrial fibrillation
- NSAIDs, non-steroidal anti-inflammatory drugs
- OR, odds ratio
- atrial fibrillation
- stroke risk
Statistics from Altmetric.com
Published Online First 30 December 2005
This study was funded by a grant from AstraZeneca. IC was also funded by a grant from the Wellcome Trust. SDeW was funded by the BUPA foundation.
Competing interests: AstraZeneca funded this study and have interests in stroke prophylaxis. NR is a director of a company providing DIN-LINK data for commercial purposes.